NIH Licenses Gene-Editing Breakthrough to Cure Rare ROSAH Syndrome Vision Loss
Published Date: 3/20/2026
Notice
Summary
The National Institutes of Health is offering a cool new gene-editing invention that can fix a rare genetic disease called ROSAH syndrome, which causes vision loss and other problems. Companies can license this technology to develop treatments that might restore vision and improve lives. Interested parties should act soon and be ready to sign a confidentiality agreement to get all the details.
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
Potential Vision-Restoring Therapy For ROSAH
Researchers report a gene-editing method that precisely repairs the ALPK1 p.Thr237Met mutation in patient-derived cells with high accuracy and no side effects in lab tests, and the therapy could be delivered to the eye or salivary glands or via corrected patient cells returned to the patient. This technology could, if developed and commercialized, offer personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.
Government Gene-Editing Available for Licensing
The National Institute of Allergy and Infectious Diseases (NIAID) is offering a gene-editing technology that fixes the ALPK1 p.Thr237Met mutation (causing ROSAH syndrome) for licensing to commercial developers under 35 U.S.C. 209 and 37 CFR part 404. Companies interested in commercializing the invention should reference HHS Reference No. E-044-2024-0 when contacting the licensing office.
Agency Seeking Research Collaborators
NIAID is seeking statements of capability or interest from parties for collaborative research to further develop, evaluate, or commercialize this technology, with specific interest in human clinical trials. Parties that want to collaborate should contact David Yang at 240-695-6406 or [email protected].
Patent Filings Extend Market Coverage
Intellectual property associated with this invention includes Provisional Patent Application No. 63/733,836 filed December 13, 2024, and PCT Patent Application No. PCT/US2025/059432 filed December 12, 2025; foreign patent applications have been filed on selected inventions and may be available for licensing to extend market coverage. Reference: HHS Reference No. E-044-2024-0.
Technology Is At Pre-Clinical Stage
The notice states the invention's development stage as "Pre-Clinical," indicating it has laboratory results but has not yet entered human clinical trials. NIAID specifically notes interest in collaborators for human clinical trials to advance development.
Confidentiality Agreement Needed For Details
To receive copies of unpublished information about the invention, interested parties must sign a Confidential Disclosure Agreement (CDA) before NIAID will share full details. Contact David Yang at 240-695-6406 or [email protected] to request information and the CDA.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2026-05526, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on April 16, 2026, to review and evaluate grant applications and contract proposals. These meetings protect private info and trade secrets, so the public can’t attend. Researchers and organizations applying for funding should note these important review dates as they impact which projects get supported.
Next: 2026-05528, Agency Information Collection Activities; Comment Request; State Workforce Program Certification
The Department of Education wants your thoughts on a new form for State Workforce Programs to certify their info. This helps make sure the government collects only what’s needed without extra hassle. If you’re involved with these programs, you can comment by May 19, 2026—no cost changes, just smoother paperwork!